Your browser is no longer supported. Please, upgrade your browser.
EDIT Editas Medicine, Inc. daily Stock Chart
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.67 Insider Own0.20% Shs Outstand57.74M Perf Week-8.62%
Market Cap1.14B Forward P/E- EPS next Y-3.31 Insider Trans-5.07% Shs Float53.55M Perf Month-12.72%
Income-133.70M PEG- EPS next Q-0.77 Inst Own78.60% Short Float15.90% Perf Quarter-32.78%
Sales20.50M P/S55.85 EPS this Y-14.60% Inst Trans6.78% Short Ratio8.90 Perf Half Y-12.80%
Book/sh5.03 P/B3.94 EPS next Y-4.70% ROA-33.10% Target Price35.86 Perf Year-19.75%
Cash/sh7.92 P/C2.50 EPS next 5Y- ROE-60.60% 52W Range14.01 - 34.37 Perf YTD-33.03%
Dividend- P/FCF- EPS past 5Y-46.80% ROI-53.70% 52W High-46.00% Beta2.12
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low32.48% ATR2.21
Employees208 Current Ratio7.70 Sales Q/Q101.60% Oper. Margin- RSI (14)41.79 Volatility8.41% 12.02%
OptionableYes Debt/Eq0.00 EPS Q/Q-38.70% Profit Margin- Rel Volume0.92 Prev Close19.83
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 AMC Payout- Avg Volume956.90K Price18.56
Recom2.20 SMA20-8.28% SMA50-22.29% SMA200-25.40% Volume677,768 Change-6.40%
Feb-21-20Initiated Wells Fargo Equal Weight $28
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Mar-27-20 11:31AM  Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue? Zacks
Mar-19-20 10:40AM  Editas Medicine (EDIT) Catches Eye: Stock Jumps 9% Zacks +9.35%
Mar-11-20 09:20PM  Edited Transcript of EDIT earnings conference call or presentation 26-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -6.63%
Mar-05-20 08:29AM  Editas, Allergan Start Dosing in Early-Stage Eye Disease Study Zacks +9.30%
Mar-04-20 05:00AM  Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 GlobeNewswire
Feb-28-20 09:06AM  Editas Medicine, Inc. Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St. +5.72%
Feb-27-20 02:56PM  Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates Zacks -6.38%
Feb-26-20 05:25PM  Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:02PM  Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update GlobeNewswire
Feb-19-20 04:02PM  Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update GlobeNewswire
Feb-17-20 07:12AM  How Many Editas Medicine, Inc. (NASDAQ:EDIT) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Feb-06-20 12:30PM  Shares of gene-editing startup Beam jump 40% after upsized IPO American City Business Journals
Feb-03-20 11:27AM  Andreas Halvorsen Trims Adaptive Biotechnologies Stake
Jan-17-20 02:09PM  European ruling threatens Broad's CRISPR gene-editing patents American City Business Journals
Jan-13-20 09:00AM  Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference GlobeNewswire
08:55AM  Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer GlobeNewswire
Jan-10-20 04:30PM  Editas Medicine Reports Inducement Grants to New Chief Financial Officer GlobeNewswire
05:59AM  Implied Volatility Surging for Editas (EDIT) Stock Options Zacks
Jan-09-20 09:00AM  Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth GlobeNewswire
Jan-06-20 11:00PM  Crispr puts first human in-body gene editing to test Financial Times
09:45AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
Jan-02-20 09:00AM  Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-30-19 04:07PM  Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison Investor's Business Daily
03:40PM  Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial Yahoo Finance Video
Dec-24-19 12:00PM  Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should Know Zacks
Dec-19-19 09:15AM  Editas Medicine (NASDAQ:EDIT) Shareholders Booked A 90% Gain In The Last Three Years Simply Wall St.
Dec-14-19 08:42PM  Did Hedge Funds Drop The Ball On Editas Medicine, Inc. (EDIT) ? Insider Monkey
Dec-12-19 11:30AM  Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report? Zacks
Dec-09-19 06:00PM  Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
Dec-03-19 01:03AM  Don't Judge a Month by its First Day Zacks
Dec-02-19 11:43AM  Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-20-19 09:41AM  Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher Zacks
09:12AM  Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
01:05AM  The NASDAQ Needs No Break Zacks
Nov-19-19 10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals +7.82%
Nov-13-19 10:00AM  Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal Zacks
Nov-12-19 08:35AM  Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates Zacks +9.47%
07:02AM  Editas Medicine Announces Third Quarter 2019 Results and Update GlobeNewswire
07:00AM  Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases GlobeNewswire
Nov-05-19 08:00AM  Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update GlobeNewswire
Oct-31-19 04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 11:10AM  Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-19 04:05PM  Experts Talk Hot Biotech Stocks at Barrons Breakfast
Oct-28-19 06:55PM  Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer GlobeNewswire
12:10PM  Is Editas Medicine, Inc. (EDIT) Going to Burn These Hedge Funds? Insider Monkey
Oct-23-19 10:32AM  Moving Average Crossover Alert: Editas Medicine Zacks
Oct-19-19 10:29AM  Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth Simply Wall St.
Oct-16-19 12:16PM  Editas Inks Deal for Gene Editing Neurological Disease Drugs Zacks
10:13AM  CRISPR Therapeutics Enters New License Agreement, Shares Up Zacks
Oct-15-19 06:15PM  Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases GlobeNewswire
Oct-07-19 07:00AM  Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines GlobeNewswire
Oct-01-19 08:00AM  Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-13-19 10:06AM  Adverum Reports Data From Phase I Wet AMD Study, Stock Down Zacks
Sep-06-19 03:07PM  ETFs Poised to Benefit from Gene Editing Revolution Zacks
Sep-05-19 09:31AM  Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report? Zacks
09:15AM  How Boulder biotech companies are putting Colorado on the gene-editing map American City Business Journals
Sep-04-19 12:52PM  Need To Know: Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Have Been Buying Shares Simply Wall St.
Aug-29-19 08:00AM  Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-27-19 09:10AM  CRISPR gene-editing technique set to push new boundaries MarketWatch
Aug-13-19 08:27PM  Edited Transcript of EDIT earnings conference call or presentation 6-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-12-19 04:05PM  Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors GlobeNewswire
Aug-08-19 10:09AM  Bayer buys Cambridge cell therapy startup BlueRock at $1B value American City Business Journals
09:50AM  Editas Medicine, Inc. (EDIT) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 09:32AM  Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO Zacks
Aug-06-19 09:10PM  Editas Medicine Remains on Track Motley Fool
06:05PM  Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:15PM  Editas Medicine Announces Second Quarter 2019 Results and Update GlobeNewswire
Aug-01-19 06:16AM  Legal fight over Broad Institute's patent for CRISPR gene editing flares up again American City Business Journals
Jul-31-19 12:41PM  Is Intellia Therapeutics a Buy? Motley Fool -5.82%
Jul-30-19 04:02PM  Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update GlobeNewswire
Jul-29-19 10:34AM  Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-25-19 09:00AM  Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10 GlobeNewswire
Jul-23-19 04:44PM  CRISPR Could Change Medicine, But Not in the Way Wall Street Expects Motley Fool
Jul-10-19 08:16AM  Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June Motley Fool
Jul-07-19 07:32AM  Is Editas Medicine a Buy? Motley Fool
Jul-05-19 08:57AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
Jul-04-19 12:47PM  What Kind Of Shareholders Own Editas Medicine, Inc. (NASDAQ:EDIT)? Simply Wall St.
Jul-01-19 11:12PM  How to Invest in Biotech Stocks Motley Fool
09:15AM  Stocks Soar 7% in June Zacks
Jun-25-19 10:19AM  Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy? Insider Monkey
Jun-15-19 11:30AM  Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association GlobeNewswire
Jun-14-19 09:00AM  Glaxo Inks Genome Research Deal With University of California Zacks
Jun-11-19 06:00AM  Is the Newest Gene Editing Stock a Buy? Motley Fool
Jun-10-19 09:29AM  CRISPR Therapeutics Up on Collaboration Expansion by Vertex Zacks
Jun-07-19 07:45AM  Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far Motley Fool +8.89%
Jun-06-19 09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals
May-20-19 04:14PM  Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study Zacks
May-19-19 10:58PM  Edited Transcript of EDIT earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-17-19 06:00AM  3 Small-Cap Biotech Stocks You Can Buy Right Now Motley Fool
May-10-19 10:11AM  Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil Zacks
May-09-19 03:03PM  IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus Zacks
May-08-19 05:28PM  Editas Gears Up for a Busy 2019 Motley Fool
12:23AM  Editas Medicine, Inc. (EDIT) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:05PM  Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:57PM  Editas: 1Q Earnings Snapshot Associated Press
04:01PM  Editas Medicine Announces First Quarter 2019 Results and Update GlobeNewswire
06:01AM  After $59M round, CRISPR startup launches with plans to tackle heart disease American City Business Journals
May-06-19 09:58AM  Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up Zacks
09:44AM  ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 Zacks
May-03-19 03:40PM  Did Changing Sentiment Drive Editas Medicine's (NASDAQ:EDIT) Share Price Down By 27%? Simply Wall St.
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Albright CharlesChief Scientific OfficerFeb 07Sale26.9562216,76331,524Feb 10 04:34 PM
Albright CharlesChief Scientific OfficerFeb 03Sale26.545,549147,28820,553Feb 04 05:24 PM
Albright CharlesChief Scientific OfficerJan 31Option Exercise0.0017,977026,102Feb 04 05:24 PM
Collins CynthiaCEOAug 19Sale25.835,193134,13511,373Aug 21 04:03 PM